A Long-Lasting HIV Vaccine for Initial Infection Sites
Durable HIV Vaccine Targeting Mucosal Epithelium
['FUNDING_R01'] · TEXAS BIOMEDICAL RESEARCH INSTITUTE · NIH-11135490
This project is working to create a strong, long-lasting vaccine that protects against HIV right where the virus tries to enter the body.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TEXAS BIOMEDICAL RESEARCH INSTITUTE (nih funded) |
| Locations | 1 site (SAN ANTONIO, UNITED STATES) |
| Trial ID | NIH-11135490 on ClinicalTrials.gov |
What this research studies
This research aims to develop an HIV vaccine that provides two layers of protection: an initial barrier at the body's entry points, like mucosal tissues, and a second set of defenses throughout the body if the first barrier is breached. The goal is to keep the immune system constantly alert to HIV and target the immune response specifically to the initial infection sites. This innovative strategy uses epithelial stem cells to continuously present viral antigens, aiming to build solid, long-term protection against the virus.
Who could benefit from this research
Good fit: Future participants in related clinical trials would likely be healthy individuals at risk of HIV exposure.
Not a fit: Patients already living with HIV would not directly benefit from this preventative vaccine.
Why it matters
Potential benefit: If successful, this vaccine could offer a new way to prevent HIV infection by providing robust, long-term protection at the body's primary entry points.
How similar studies have performed: While previous HIV vaccine efforts have provided valuable insights, this project explores an original strategy for delivering a vaccine to mucosal sites.
Where this research is happening
SAN ANTONIO, UNITED STATES
- TEXAS BIOMEDICAL RESEARCH INSTITUTE — SAN ANTONIO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GAUDUIN, MARIE-CLAIRE ELISABETH — TEXAS BIOMEDICAL RESEARCH INSTITUTE
- Study coordinator: GAUDUIN, MARIE-CLAIRE ELISABETH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome, Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome, Acquired Immunodeficiency Syndrome Virus